Chip Ganassi Racing Teams, Novo Nordisk and Charlie Kimball Unveil New INDYCAR Livery to Showcase Tresiba® (insulin degludec injection 200 Units/mL) at Phoenix Grand Prix

The New Look Represents the Next Phase in Kimball’s Journey With Diabetes and the Race with Insulin® Awareness Campaign


INDIANAPOLIS (March 28, 2016) – Chip Ganassi Racing Teams, INDYCAR driver Charlie Kimball and Novo Nordisk, a world leader in diabetes care, w ill unveil a new livery for the No. 83 entry fielded by Novo Nordisk Chip Ganassi Racing when the car takes the track at the Phoenix Grand Prix. The car features a new black and green color scheme and carries the logo of Tresiba® (insulin degludec injection), Novo Nordisk’s once-daily, long-acting basal insulin. Tresiba® was approved by the U.S. Food and Drug Administration (FDA) in September 2015.1

The 2016 race season marks the eighth consecutive year of partnership between Novo Nordisk and Kimball. Since his type 1 diabetes diagnosis, Kimball has been a passionate diabetes advocate. He is the face of Novo Nordisk’s award-winning Race with Insulin® campaign, which aims to raise awareness and educate the public about diabetes management.

“The new look of this car represents something very personal to me. Just as there have been advancements in racing, there have been advancements in the management of diabetes. The new look of my 2016 car represents another strong link between this program and the diabetes community,” said Kimball. “I am excited about the new design, not only because of the new look, but also because it represents the next phase in my effort to educate others.”

“We love the new look of Charlie’s car and are thrilled to continue our partnership with Charlie and Chip Ganassi Racing. It has been rewarding to see Charlie inspire and educate others affected by diabetes,” said Camille Lee, senior vice president, Diabetes & Obesity Marketing, Novo Nordisk Inc. “We are looking forward to a great season with Charlie and the No. 83 Tresiba® Chevrolet®, and are extremely excited about the future of the Race with Insulin® campaign.”

Continue to follow Charlie’s journey and his work with Novo Nordisk at, learn more about Tresiba® (insulin degludec injection 200 Units/mL) at, or follow Charlie on Twitter at @racewithinsulin.


About Tresiba®

Tresiba® is a long-acting insulin that lasts at least 42 hours after the last of eight

once-daily injections (0.4 U/kg), and has a consistently flat and stable profile at steady state.1 Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® should take their dose as soon as they remember, then continue with their regular dosing schedule, making sure there are at least eight hours between doses.1-3 Tresiba® is available in Novo Nordisk’s insulin delivery device – FlexTouch® – as a 100 units/mL or 200 units/mL pen. Tresiba® U-200 FlexTouch® can dose up to 160 units in a single injection. FlexTouch® is also the only prefilled insulin pen with no push-button extension.1


What is Tresiba®?


  • Prescription Tresiba®is a long-acting insulin used to control high blood sugar in adults with diabetes
  • Tresiba®is not for people with diabetic ketoacidosis
  • Tresiba®is available in 2 concentrations: 200 units/mL and 100 units/mL
  • It is not known if Tresiba®is safe and effective in children under 18 years of age


Important Safety Information

Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

Who should not take Tresiba®?

Do not take Tresiba® if you:

  • are having an episode of low blood sugar
  • are allergic to Tresiba®or any of the ingredients in Tresiba®

Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:

  • pregnant, planning to become pregnant, or are breastfeeding
  • taking new prescription or over-the-counter medicines, vitamins, or herbal supplements

Talk to your health care provider about low blood sugar and how to manage it.

How should I take Tresiba®?

  • Read the Instructions for Use and take Tresiba®(insulin degludec injection 200 Units/mL) exactly as your health care provider tells you to
  • Do not do any conversion of your dose. The dose counter always shows the selected dose in units
  • Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to
  • If you miss or are delayed in taking your dose of Tresiba®:
  • Take your dose as soon as you remember, then continue with your regular dosing schedule
  • Make sure there are at least 8 hours between doses
  • Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them
  • Do not reuse or share your needles with other people. You may give them a serious infection, or get a serious infection from them
  • Never inject Tresiba®(insulin degludec injection 200 Units/mL) into a vein or muscle
  • Never use a syringe to remove Tresiba®from the FlexTouch® pen


What should I avoid while taking Tresiba®?

  • Do notdrive or operate heavy machinery, until you know how Tresiba® affects you
  • Do notdrink alcohol or use prescription or over-the-counter medicines that contain alcohol


What are the possible side effects of Tresiba®?

Tresiba® may cause serious side effects that can be life-threatening, including:

  • Low blood sugar (hypoglycemia).Signs and symptoms that may indicate low blood sugar include anxiety, irritability, mood changes, dizziness, sweating, confusion, and headache
  • Low potassium in your blood (hypokalemia)
  • Heart failurein some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Tresiba®. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain


Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress,

What are the possible side effects of Tresiba®?

Common side effects may include reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.

Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.

Please click here for Prescribing Information.


About Diabetes

In the United States, more than 29 million people are affected by diabetes.4 Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases.4 Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has almost quadrupled over the past 30 years.5